FINWIRES · TerminalLIVE
FINWIRES

Japanese Stocks Fall as Trump Vows Hormuz Blockade After Failed Iran Talks

-- Japanese stocks fell at the start of the trading week following the breakdown of US-Iran negotiations, amplified by Trump's vow of an immediate U.S. Navy blockade of the Strait of Hormuz.

The Nikkei 225 opened lower by 502.7 points, or 0.9%, at 56,421.46.

Brent crude breached the $100-mark again amid fears the US blockade would disrupt energy flows through the strategic waterway.

Trump, on his social media post, declared that Washington would intercept any ship that paid Tehran for secure transit through the strait and would also remove any mines present in the waterway.

Meanwhile, the U.S. Central Command stated that American forces would enforce a halt to all maritime traffic entering or departing Iranian ports starting Monday at 10 a.m. New York time.

Friday's economic data revealed a sharp rise in U.S. consumer prices - the largest since 2022 - though the core inflation reading was relatively moderate, along with a decline in consumer sentiment.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062